高密度多重诊断测试的全球市场

到 2030 年，全球高密度多重诊断测试市场预计将达到 55 亿美元

全球高密度多重诊断测试市场预计 2023 年为 21 亿美元，预计到 2030 年将达到 55 亿美元，2023-2030 年分析期间复合年增长率为 14.8%。诊断实验室最终用途是本报告分析的细分市场之一，预计复合年增长率为 15.1%，到分析期结束时将达到 18 亿美元。分析期间，医院和诊所最终用途行业的复合年增长率预计为 14.6%。

美国市场预估为5.557亿美元，中国预期复合年增长率为13.6%

预计 2023 年美国高密度多重诊断测试市场规模将达到 5.557 亿美元。中国作为世界第二大经济体，预计2030年市场规模将达到8.191亿美元，2023-2030年分析期间复合年增长率为13.6%。其他值得注意的区域市场包括日本和加拿大，预计在分析期间复合年增长率分别为 13.4% 和 12.5%。在欧洲，德国预计复合年增长率为 10.4%。

全球高密度多重诊断测试市场—主要趋势与驱动因素总结

高密度多重诊断测试会彻底改变精准医学的未来吗？

高密度多重诊断测试正在成为推进精准医学的重要工具，但为什么这些先进的诊断平台对现代医学至关重要？高密度多重检测能够同时检测和定量一份样本中的多种生物标记物，为疾病诊断和患者健康监测提供无与伦比的效率。此类测定可以使用微阵列、次世代定序(NGS) 和以微珠为基础的系统等技术同时测试数百至数千种分析物，包括蛋白质、核酸和代谢物。它广泛应用于肿瘤学、感染疾病、免疫学和个人化医疗等领域，详细了解多种生物标记对于准确诊断和治疗至关重要。

高密度多重诊断测试的吸引力在于其能够全面、同时分析多个目标，从而减少与传统单目标测试相关的时间、成本和复杂性。此类检测使医疗保健提供者能够做的不仅仅是获得诊断见解。随着医疗保健领域转向更个人化和资料主导的方法，高密度多重诊断测试正在帮助改善患者的治疗结果、优化治疗策略并推动医疗创新，它正在成为一种重要的工具。

科技如何推进高密度多重诊断测试？

技术进步显着提高了高密度多重诊断测试的效能、灵敏度和可扩展性，使其更强大且更适合临床和研究应用。最重要的创新之一是高通量微阵列平台的开发。微阵列能够在一次测试中同时测量数千个遗传和蛋白质标记，从而能够大规模筛检和发现疾病生物标记。这些平台的灵敏度和特异性不断提高，甚至可以检测低丰度的生物标记。此外，现代微阵列变得更具成本效益和速度，使其成为常规临床诊断和大规模人群健康研究的理想选择。

次世代定序(NGS) 允许从单一样本中分析大量遗传讯息，从而彻底改变了多重诊断。基于 NGS 的检测可以以高密度形式对整个基因组、EXOME或目标基因组进行定序，从而可以同时检测各种遗传变异、突变和基因表现。这项技术有助于推进癌症诊断，并识别肿瘤内的多种基因突变，从而指导个人化治疗计划。 NGS 平台不仅提高了准确性，而且提高了速度和可扩展性，使临床实验室和研究机构更容易进行高密度多基因检测。

以微珠为基础的多重技术也取得了长足的进步。这些平台使用颜色编码的珠子同时捕获和测量不同的分析物，提供灵活且可扩展的多重分析方法。以微珠为基础的测定通常用于测量生物样本中的蛋白质、细胞激素和其他可溶性生物标记。基于以微珠为基础的系统的进步提高了灵敏度，并能够检测血液和血清等复杂样本中的低浓度生物标记。这使得以微珠为基础的检测在免疫学和发炎研究中特别有用，其中多种细胞激素和免疫标记物的检测对于了解疾病进展和免疫反应至关重要。

将自动化和机器学习整合到多重诊断平台中进一步提高了其效率和诊断能力。自动化工作流程能够以最短的手动时间执行高密度、多重检测，从而减少人为错误并提高通量。机器学习演算法被用来分析这些检测产生的大型资料集，识别难以手动检测的生物标记之间的模式和相关性。自动化和人工智慧 (AI) 的结合将帮助临床医生和研究人员从多重资料中获得更有意义的见解，提高诊断准确性，并在患者照护方面做出更明智的决策。

与传统技术相比，数位多重技术（例如数位 PCR (dPCR)）还透过提供更高的灵敏度和准确性而先进的高密度多重检测。 dPCR 能够在极低浓度下对特定 DNA 或 RNA 序列进行定量，使其成为液态切片等应用的理想选择，在这些应用中，检测罕见基因突变和循环肿瘤DNA 对于癌症的早期检测和监测至关重要。透过将样本分成数千个单独的反应，dPCR 实现了高精度并减少了背景噪音的影响，使其能够检测到最细微的基因变化。

为什么高密度多重诊断测试对于现代医疗保健和研究至关重要？

为什么高密度多重诊断测试对于现代医疗保健和研究至关重要：对单一样本中的多个生物标记进行全面、高通量的分析可以更详细、更准确地了解疾病状态，因为它会的。例如，在肿瘤学领域，这些检测允许临床医生分析肿瘤样本中的多种基因突变、蛋白质表达和免疫标记物，从而根据每个患者癌症的独特分子特征进行个性化製定治疗计划。透过同时识别多个生物标记物，高密度多重检测可以指导标靶治疗、免疫疗法和联合治疗，以改善治疗结果并降低副作用风险。

在感染疾病诊断中，高密度多重检测对于在单次测试中检测多种病原体或病毒变异体特别有用。例如，在 COVID-19 大流行期间，使用多重检测来测试一份样本中的 SARS-CoV-2 病毒和其他呼吸道病原体的不同病毒株。这种对单一检体进行全面检测的能力对于诊断合併感染、监测病毒的演变和追踪变种的传播至关重要，这对于公共卫生监测和应对工作至关重要。

在免疫学和自体免疫疾病中，多重检测使研究人员和临床医生能够测量多种免疫标记物，例如细胞激素、趋化素和抗体，以深入了解免疫反应和疾病进展。这些检测用于诊断复杂的免疫介导的疾病，例如类风湿性关节炎、狼疮和多发性硬化症，这些疾病需要对多种生物标记进行详细分析以了解潜在的免疫失调。多重检测在疫苗开发和免疫治疗中也发挥重要作用，测量多重免疫反应对于评估功效和安全性至关重要。

个人化医疗的兴起进一步凸显了高密度多重诊断测试的重要性。个人化医疗依赖对个别分子和基因组成的详细了解来客製化最有效的治疗方法。多重检测可以同时分析多种基因突变、基因表现和表观遗传标记，从而更全面地了解患者的疾病概况。这在癌症治疗中尤其重要，因为多种基因突变可以驱动肿瘤生长，必须根据肿瘤中存在的特定突变选择标靶治疗。高密度多重检测可实现这种精确度，从而实现更有效和个人化的治疗策略。

药物基因体学使用高密度多重检测来识别影响患者药物代谢的遗传变异。这些资讯有助于临床医生为个别患者选择最有效的药物和剂量，降低药物不良反应的风险并改善治疗结果。透过同时分析多个基因突变，这些检测可以更全面地了解患者的基因谱，从而实现更安全、更有效的药物管理。

在学术和临床研究中，高密度多重检测在大规模生物标记发现、群体研究和临床试验中非常有用。研究人员利用这些检测来识别新的疾病生物标记物，研究疾病的遗传和分子基础，并评估新治疗方法的有效性。同时分析数百至数千个生物标记的能力可以实现更全面的研究和更快的资料生成，从而加快科学发现的步伐并提高临床试验的品质。

推动高密度多重诊断测试市场成长的因素有哪些？

高密度多重诊断测试市场的成长受到多种因素的推动，包括对精准医疗的需求不断增长、个性化和标靶治疗治疗的兴起、生物标誌物发现的进步以及医疗保健和研究领域对高通量诊断的持续需求. 重要因素带来的。关键驱动因素之一是世界向精准医疗的转变，精准医疗透过详细了解每位患者的生物学特征来实现个人化治疗。高密度多重检测能够同时分析多种生物标记物，提供製定个人化治疗计画所需的分子洞察力，特别是在癌症、自体免疫疾病和罕见遗传疾病方面。

基于生物标记的治疗方法的使用越来越多，尤其是在肿瘤学领域，也推动了对高密度多重检测的需求。随着针对特定基因突变和蛋白质标记物的癌症治疗方法的开发，临床医生需要能够分析肿瘤样本中多种生物标记物的工具，以选择最合适的治疗方法。高密度多重检测能够对这些生物标记进行全面分析，使临床医生能够识别患者癌症的分子驱动因素并相应地调整治疗。因此，多重检测已广泛应用于癌症诊断和药物开发。

次世代定序仪（NGS）和其他高通量技术的持续成长也有助于多重诊断分析市场的扩张。随着NGS变得更加容易获得和具有成本效益，它在基因检测、癌症筛检和罕见疾病诊断等临床环境中的使用正在增加。基于NGS的多重检测可以分析多种遗传变异，与传统的单基因检测相比，可以进行更详细、更准确的诊断。随着 NGS 平台可用性的增加，对多重检测的需求不断增长，这些检测可以利用定序技术的力量来提供全面的遗传见解。

生物标记发现和检验的进步也推动了对多重诊断分析的需求。随着从癌症到心血管疾病等多种疾病的新生物标记的研究和鑑定，人们越来越需要能够在一次测试中检测多种生物标记的诊断工具。高密度多重检测适合此目的，因为它们可以同时分析多种疾病相关的生物标记物，从而实现更全面、更准确的诊断。因此，多重检测越来越多地被用于生物标记发现和验证研究，特别是在药物开发和临床试验中。

传染病检查对高通量诊断的需求也加速了高密度多重诊断检测市场的成长。 COVID-19 大流行凸显了对快速、可扩展的诊断解决方案的需求，该解决方案可以在一次测试中检测多种病原体和病毒变体。多重检测在识别合併感染、监测 SARS-CoV-2 变种的传播和指南公共卫生干预方面发挥了重要作用。随着新兴感染疾病的威胁持续存在，对能够提供全面、快速结果的多重诊断平台的需求预计将会增加。

此外，对成本效益诊断的日益关注正在推动对多重检测的需求。传统的诊断测试通常需要多个样本、试剂和测试来分析不同的生物标记物，导致成本高且交货时间长。相较之下，高密度多重检测允许同时分析单一样本中的多个生物标记物，从而减少了额外测试的需要并降低了总体成本。这种成本效益在大规模临床试验、人口健康研究和常规诊断中尤其重要，因为效率和扩充性非常重要。

由于技术进步、对个人化医疗的日益关注以及医疗保健和研究领域对高通量诊断的需求，高密度多重诊断测试市场有望显着成长。随着这些检测方法的不断发展，它们将在提高诊断准确性、优化治疗策略和推进精准医学领域中发挥越来越重要的作用。

受访企业范例（共12家）

• Abbott Laboratories
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Erba Diagnostics, Inc.
• F. Hoffmann-La Roche AG
• Gold Standard Diagnostics Corporation
• Hologic, Inc.
• Luminex Corporation
• Randox Laboratories Ltd.
• Thermo Fisher Scientific, Inc.

目录

第一章调查方法

第 2 章执行摘要

• 市场概况
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 其他欧洲国家
• 亚太地区
• 其他领域

第四章 比赛

Global High-Density Multiplexed Diagnostic Assays Market to Reach US$5.5 Billion by 2030

The global market for High-Density Multiplexed Diagnostic Assays estimated at US$2.1 Billion in the year 2023, is expected to reach US$5.5 Billion by 2030, growing at a CAGR of 14.8% over the analysis period 2023-2030. Diagnostic Laboratories End-Use, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Hospitals & Clinics End-Use segment is estimated at 14.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$555.7 Million While China is Forecast to Grow at 13.6% CAGR

The High-Density Multiplexed Diagnostic Assays market in the U.S. is estimated at US$555.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$819.1 Million by the year 2030 trailing a CAGR of 13.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.4% and 12.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Global High-Density Multiplexed Diagnostic Assays Market - Key Trends and Drivers Summarized

Are High-Density Multiplexed Diagnostic Assays Revolutionizing the Future of Precision Medicine?

High-density multiplexed diagnostic assays are emerging as a critical tool in advancing precision medicine, but what makes these sophisticated diagnostic platforms so essential for modern healthcare? High-density multiplexed assays allow for the simultaneous detection and quantification of multiple biomarkers from a single sample, offering unparalleled efficiency in diagnosing diseases and monitoring patient health. These assays can test for hundreds or even thousands of analytes—such as proteins, nucleic acids, or metabolites—at once, using technologies like microarrays, next-generation sequencing (NGS), or bead-based systems. They are extensively used in fields such as oncology, infectious diseases, immunology, and personalized medicine, where a detailed understanding of multiple biomarkers is essential for accurate diagnosis and treatment.

The appeal of high-density multiplexed diagnostic assays lies in their ability to provide comprehensive and simultaneous analysis of multiple targets, which reduces the time, cost, and complexity associated with traditional single-target tests. These assays offer more than just diagnostic insights—they enable healthcare providers to better understand the molecular mechanisms underlying diseases, tailor treatment plans to individual patients, and monitor treatment responses with greater precision. As the healthcare landscape shifts towards more personalized and data-driven approaches, high-density multiplexed diagnostic assays are becoming indispensable tools in improving patient outcomes, optimizing therapeutic strategies, and driving medical innovation.

How Has Technology Advanced High-Density Multiplexed Diagnostic Assays?

Technological advancements have significantly enhanced the performance, sensitivity, and scalability of high-density multiplexed diagnostic assays, making them more powerful and accessible for clinical and research applications. One of the most important innovations has been the development of high-throughput microarray platforms. Microarrays allow the simultaneous measurement of thousands of genetic or protein markers in a single test, enabling large-scale screening and discovery of disease biomarkers. These platforms have evolved to offer increased sensitivity and specificity, allowing for the detection of even low-abundance biomarkers. Modern microarrays are also more cost-effective and faster, making them ideal for routine clinical diagnostics and large-scale population health studies.

Next-generation sequencing (NGS) has revolutionized multiplexed diagnostics by enabling the analysis of vast amounts of genetic information from a single sample. NGS-based assays can sequence entire genomes, exomes, or targeted panels of genes in a high-density format, making it possible to detect a wide array of genetic variants, mutations, and gene expression profiles simultaneously. This technology has been instrumental in advancing cancer diagnostics, where identifying multiple genetic mutations in tumors can guide personalized treatment plans. NGS platforms have improved not only in terms of accuracy but also in terms of speed and scalability, making high-density multiplexed genetic assays more accessible to clinical laboratories and research institutions.

Bead-based multiplexing technologies have also made significant strides. These platforms use color-coded beads to simultaneously capture and measure different analytes, offering a flexible and scalable approach to multiplexing. Bead-based assays are commonly used for measuring proteins, cytokines, and other soluble biomarkers in biological samples. Advances in bead-based systems have increased their sensitivity, enabling the detection of low-abundance biomarkers in complex samples, such as blood or serum. This makes bead-based assays particularly useful for immunology and inflammation research, where detecting multiple cytokines or immune markers is essential for understanding disease progression and immune responses.

The integration of automation and machine learning into multiplexed diagnostic platforms has further enhanced their efficiency and diagnostic capabilities. Automated workflows enable high-density multiplexed assays to be performed with minimal hands-on time, reducing human error and increasing throughput. Machine learning algorithms are being used to analyze the large datasets generated by these assays, identifying patterns and correlations between biomarkers that might be difficult to detect manually. This combination of automation and artificial intelligence (AI) is helping clinicians and researchers extract more meaningful insights from multiplexed data, improving diagnostic accuracy and enabling more informed decision-making in patient care.

Digital multiplexing technologies, such as digital PCR (dPCR), have also advanced high-density multiplexed assays by offering higher sensitivity and precision compared to traditional techniques. dPCR enables the quantification of specific DNA or RNA sequences at extremely low concentrations, making it ideal for applications such as liquid biopsy, where detecting rare genetic mutations or circulating tumor DNA is critical for early cancer detection and monitoring. By partitioning the sample into thousands of individual reactions, dPCR achieves high accuracy and reduces the impact of background noise, allowing for the detection of even the most subtle genetic changes.

Why Are High-Density Multiplexed Diagnostic Assays Critical for Modern Healthcare and Research?

High-density multiplexed diagnostic assays are critical for modern healthcare and research because they offer comprehensive, high-throughput analysis of multiple biomarkers from a single sample, providing a more detailed and accurate understanding of disease states. In the field of oncology, for instance, these assays enable clinicians to profile multiple genetic mutations, protein expressions, and immune markers in tumor samples, allowing for personalized treatment plans tailored to the specific molecular characteristics of each patient's cancer. By identifying multiple biomarkers simultaneously, high-density multiplexed assays can guide the use of targeted therapies, immunotherapies, and combination treatments, improving treatment outcomes and reducing the risk of adverse effects.

In infectious disease diagnostics, high-density multiplexed assays are particularly valuable for detecting multiple pathogens or variants of a virus in a single test. During the COVID-19 pandemic, for example, multiplexed assays were used to test for different strains of the SARS-CoV-2 virus, as well as other respiratory pathogens, in a single sample. This ability to perform comprehensive testing from a single specimen is critical for diagnosing co-infections, monitoring viral evolution, and tracking the spread of variants, which is essential for public health surveillance and response efforts.

In immunology and autoimmune diseases, multiplexed assays allow researchers and clinicians to measure a wide range of immune markers, such as cytokines, chemokines, and antibodies, providing insights into the immune response and disease progression. These assays are used to diagnose complex immune-related conditions, such as rheumatoid arthritis, lupus, and multiple sclerosis, where a detailed analysis of multiple biomarkers is necessary to understand the underlying immune dysregulation. Multiplexed assays also play a key role in vaccine development and immunotherapy, where measuring multiple immune responses is critical for assessing efficacy and safety.

The rise of personalized medicine has further highlighted the importance of high-density multiplexed diagnostic assays. Personalized medicine relies on a detailed understanding of an individual's molecular and genetic makeup to tailor treatments that are most likely to be effective. Multiplexed assays enable the simultaneous analysis of multiple genetic mutations, gene expressions, and epigenetic markers, providing a more comprehensive picture of a patient's disease profile. This is especially important in cancer treatment, where multiple genetic mutations may drive tumor growth, and targeted therapies must be chosen based on the specific mutations present in the tumor. High-density multiplexed assays enable this level of precision, allowing for more effective and personalized treatment strategies.

In pharmacogenomics, high-density multiplexed assays are used to identify genetic variations that affect how patients metabolize drugs. This information helps clinicians choose the most effective medications and dosages for individual patients, reducing the risk of adverse drug reactions and improving therapeutic outcomes. By analyzing multiple genetic variants at once, these assays provide a more complete understanding of a patient's genetic profile, allowing for safer and more effective medication management.

In academic and clinical research, high-density multiplexed assays are invaluable for large-scale biomarker discovery, population studies, and clinical trials. Researchers use these assays to identify new disease biomarkers, study the genetic and molecular basis of diseases, and evaluate the efficacy of new treatments. The ability to analyze hundreds or thousands of biomarkers simultaneously allows for more comprehensive studies and faster data generation, accelerating the pace of scientific discovery and improving the quality of clinical trials.

What Factors Are Driving the Growth of the High-Density Multiplexed Diagnostic Assays Market?

The growth of the high-density multiplexed diagnostic assays market is driven by several key factors, including the increasing demand for precision medicine, the rise of personalized and targeted therapies, advancements in biomarker discovery, and the ongoing need for high-throughput diagnostics in healthcare and research. One of the primary drivers is the global shift towards precision medicine, which relies on a detailed understanding of individual patient biology to tailor treatments. High-density multiplexed assays enable the simultaneous analysis of multiple biomarkers, providing the molecular insights necessary for developing personalized treatment plans, particularly in cancer, autoimmune diseases, and rare genetic disorders.

The increasing use of biomarker-based therapies, particularly in oncology, is also driving demand for high-density multiplexed assays. As more cancer treatments are developed that target specific genetic mutations or protein markers, clinicians need tools that can profile multiple biomarkers in tumor samples to select the most appropriate therapy. High-density multiplexed assays allow for the comprehensive analysis of these biomarkers, enabling clinicians to identify the molecular drivers of a patient's cancer and tailor treatment accordingly. This has led to the widespread adoption of multiplexed assays in oncology diagnostics and drug development.

The ongoing growth of next-generation sequencing (NGS) and other high-throughput technologies is also contributing to the expansion of the multiplexed diagnostic assays market. As NGS becomes more accessible and cost-effective, it is increasingly being used in clinical settings for genetic testing, cancer screening, and rare disease diagnosis. NGS-based multiplexed assays can analyze a wide array of genetic variants, providing a more detailed and accurate diagnosis than traditional single-gene tests. The increasing availability of NGS platforms is driving demand for multiplexed assays that can leverage the power of sequencing technology to provide comprehensive genetic insights.

Advancements in biomarker discovery and validation are also fueling the demand for multiplexed diagnostic assays. As researchers identify new biomarkers for diseases ranging from cancer to cardiovascular disorders, there is a growing need for diagnostic tools that can detect multiple biomarkers in a single test. High-density multiplexed assays are well-suited for this purpose, as they can analyze multiple disease-related biomarkers simultaneously, providing a more comprehensive and accurate diagnosis. This has led to increased adoption of multiplexed assays in biomarker discovery and validation studies, particularly in the context of drug development and clinical trials.

The demand for high-throughput diagnostics in infectious disease testing has also accelerated the growth of the high-density multiplexed diagnostic assays market. The COVID-19 pandemic highlighted the need for rapid, scalable diagnostic solutions capable of detecting multiple pathogens or viral variants in a single test. Multiplexed assays played a crucial role in identifying co-infections, monitoring the spread of SARS-CoV-2 variants, and guiding public health interventions. As the threat of emerging infectious diseases continues, the need for multiplexed diagnostic platforms that can provide comprehensive and rapid results is expected to grow.

In addition, the growing focus on cost-effective diagnostics is driving demand for multiplexed assays. Traditional diagnostic tests often require multiple samples, reagents, and tests to analyze different biomarkers, leading to higher costs and longer turnaround times. High-density multiplexed assays, by contrast, allow for the simultaneous analysis of multiple biomarkers from a single sample, reducing the need for additional tests and lowering overall costs. This cost-effectiveness is particularly important in large-scale clinical trials, population health studies, and routine diagnostics, where efficiency and scalability are critical.

With advancements in technology, the increasing focus on personalized medicine, and the need for high-throughput diagnostics in healthcare and research, the high-density multiplexed diagnostic assays market is poised for significant growth. As these assays continue to evolve, they will play an increasingly important role in improving diagnostic accuracy, optimizing treatment strategies, and advancing the field of precision medicine.

Select Competitors (Total 12 Featured) -

• Abbott Laboratories
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Erba Diagnostics, Inc.
• F. Hoffmann-La Roche AG
• Gold Standard Diagnostics Corporation
• Hologic, Inc.
• Luminex Corporation
• Randox Laboratories Ltd.
• Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • High-Density Multiplexed Diagnostic Assays - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Expansion of Genomics and Proteomics Research Spurs Adoption of Multiplexed Diagnostic Assays
  • Growth in Use of Multiplexed Assays in Infectious Disease Diagnostics Expands Market Opportunities
  • Role of Multiplexed Diagnostic Assays in Supporting Clinical Trials and Drug Development Expands Market Reach
  • Growth in Use of High-density Multiplexed Assays in Immuno-oncology and Liquid Biopsy Fuels Market Demand
  • Expansion of Multiplexed Diagnostic Assays in Veterinary and Agricultural Applications Strengthens Market
  • Increasing Use of High-density Multiplexed Assays in Neurodegenerative Disease Research Fuels Market Growth
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World High-Density Multiplexed Diagnostic Assays Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for High-Density Multiplexed Diagnostic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • High-Density Multiplexed Diagnostic Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 11: USA Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 12: USA Historic Review for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: USA 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories and Hospitals & Clinics for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 14: Canada Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 15: Canada Historic Review for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: Canada 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories and Hospitals & Clinics for the Years 2014, 2024 & 2030
• JAPAN
  • High-Density Multiplexed Diagnostic Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 17: Japan Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Japan Historic Review for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: Japan 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories and Hospitals & Clinics for the Years 2014, 2024 & 2030
• CHINA
  • High-Density Multiplexed Diagnostic Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 20: China Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: China Historic Review for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: China 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories and Hospitals & Clinics for the Years 2014, 2024 & 2030
• EUROPE
  • High-Density Multiplexed Diagnostic Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 23: Europe Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: Europe Historic Review for High-Density Multiplexed Diagnostic Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: Europe 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 26: Europe Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories and Hospitals & Clinics for the Years 2014, 2024 & 2030
• FRANCE
  • High-Density Multiplexed Diagnostic Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 29: France Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: France Historic Review for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: France 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories and Hospitals & Clinics for the Years 2014, 2024 & 2030
• GERMANY
  • High-Density Multiplexed Diagnostic Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 32: Germany Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Germany Historic Review for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Germany 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories and Hospitals & Clinics for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 35: Italy Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Italy Historic Review for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Italy 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories and Hospitals & Clinics for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • High-Density Multiplexed Diagnostic Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 38: UK Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: UK Historic Review for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: UK 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories and Hospitals & Clinics for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Rest of Europe Historic Review for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Rest of Europe 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories and Hospitals & Clinics for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • High-Density Multiplexed Diagnostic Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Asia-Pacific Historic Review for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Asia-Pacific 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories and Hospitals & Clinics for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 47: Rest of World Recent Past, Current & Future Analysis for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Rest of World Historic Review for High-Density Multiplexed Diagnostic Assays by End-Use - Diagnostic Laboratories and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Rest of World 16-Year Perspective for High-Density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories and Hospitals & Clinics for the Years 2014, 2024 & 2030

IV. COMPETITION